Skip to main content
SpringerLink
Log in

Tocilizumab bei Riesenzellarteriitis

IL-6R-Inhibitor erhöht die Remissionsraten im Vergleich zur alleinigen Kortikosteroid-Therapie

  • journal club
  • Published:
InFo Neurologie & Psychiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Referenzen

  1. Loricera J et al. Semin Arthritis Rheum 2015; 44: 717–23

    Article  CAS  PubMed  Google Scholar 

  2. Mahr AD et al. Arthritis Rheum 2007; 56: 2789–97

    Article  CAS  PubMed  Google Scholar 

Literatur

  • Stone JH, Tuckwell K, Dimonaco S et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017; 377: 317–28

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurologische Klinik der Universität Heidelberg, Heidelberg, Deutschland

    Brigitte Wildemann (Oberärztin, Leiterin der Sektion Molekulare Neuroimmunologie)

Authors
  1. Brigitte Wildemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brigitte Wildemann.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wildemann, B. IL-6R-Inhibitor erhöht die Remissionsraten im Vergleich zur alleinigen Kortikosteroid-Therapie. InFo Neurologie 19, 30–31 (2017). https://doi.org/10.1007/s15005-017-2393-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-017-2393-9

Search

Navigation